Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
John T. Hall, CEO, sold 2,900 shares of Intapp, Inc. at $43.31 to $46.11 a share (average $45.03) in 4 transactions, worth $131K in total on Nov 2, 2026. Shares held after the trade: 5,814,808 (-0.0%).
LCNB Corp. reported net income of $7.3 million for the third quarter of 2026, up from $6.9 million in the prior year period, driven by higher net interest income. Total assets grew to $2.28 billion as of September 30, 2026, while the company maintained a strong capital position with total shareholders' equity of $282.2 million.
Onterris reported Q3 2026 financial results with revenue of $203.0 million and net income of $9.0 million, while reiterating its full-year 2026 guidance. The company also announced the completion of three small tuck-in acquisitions in the second half of 2026 and provided an update on its ongoing board-led strategic review process.
Term
Q3 2026
“Our third-quarter results demonstrate meaningful progress against our objectives for the year. Compared to prior year, we delivered higher Adjusted EBITDA, record consolidated margins and stronger cash generation despite lower reported revenue due to the normalization of episodic environmental emergency response-related recovery services. Strong growth in core consulting and water treatment services reinforces the underlying demand for our solutions, while improved project execution, favorable business mix and cost discipline are strengthening the profitability of our platform.”
Vijay Manthripragada, President and Chief Executive Officer
Net Lease Office Properties reported a net loss of $0.6 million for the third quarter of 2026, a significant improvement from the $64.1 million loss in the prior year period. The company continues its strategy of asset disposition, resulting in a net gain on sale of real estate of $38.6 million for the nine months ended September 30, 2026.
Vertex, Inc. reported third quarter 2026 total revenues of $213.3 million, an 11% increase year-over-year, driven by 20.4% growth in cloud revenues. The company achieved an Adjusted EBITDA of $64.8 million and raised its full-year 2026 revenue guidance to a range of $828.9 million to $830.9 million.
Term
Q3 2026
“The third quarter was a strong quarter for Vertex and, more importantly, clear evidence that we are delivering on our commitments to investors. We have stabilized the core business, strengthened our financial profile, and built a more efficient operating model, while seeing encouraging improvement in key growth indicators.”
Christopher Young, President and Chief Executive Officer
“Our third quarter results reflect continued progress against the priorities we established earlier this year, with solid revenue growth and a strengthened financial profile.”
Stellar V Capital Corp. held its annual general meeting on October 29, 2026, where shareholders approved an extension of the deadline to complete a business combination from October 31, 2026, to July 31, 2027. Shareholders also voted to re-elect directors and ratify the company's independent auditors.
Viasat adopted the Viasat Value Creation Incentive Program (V-CIP), a long-term performance-based equity plan designed to grant up to 2.8 million PSUs to key contributors, including CEO Mark Dankberg. The awards are tied to rigorous stock price hurdles ranging from $150 to $300 (2x to 4x the current price) and require service through December 31, 2030, to vest.
Grand Canyon Education, Inc. reported its third quarter 2026 financial results, showing a 2.4% increase in service revenue to $267.3 million. Operating income rose significantly to $51.5 million, driven by a 5.2% increase in total university partner enrollments to 145,270.
Revolution Medicines reported financial results for the third quarter of 2026, highlighted by the U.S. commercial launch of RASONQUE (daraxonrasib) for metastatic pancreatic cancer. The product generated $197.6 million in net revenue during its first five weeks on the market, with over 5,000 unique patients treated. The company also received a positive CHMP opinion for the drug in the European Union.
Term
Q3 2026
“The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union.”
Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines
Insulet Corp reported total revenue of $842.0 million for the quarter ended September 30, 2026, a significant increase from $706.3 million in the prior year period. Net income rose to $141.1 million, or $2.03 per diluted share, driven by strong gross profit margins and the absence of related-party revenue dependencies seen in 2025.
Annovis Bio stockholders approved an amendment to the 2019 Equity Incentive Plan to increase the number of authorized shares available for issuance. Additionally, stockholders approved a charter amendment to double the company's total authorized common stock from 70 million to 140 million shares.
Coherent Corp. reported strong Q1 fiscal 2027 results with revenue of $2.37 billion, a 50% increase year-over-year. The company highlighted significant growth driven by AI datacenter demand for optical connectivity and raised its long-term non-GAAP gross margin target to above 45% by the end of calendar 2028.
Term
Q1 2027
“Q1 marked a strong start to fiscal 2027, with pro forma revenue up 56% year over year and non-GAAP EPS up 80%. Our established businesses delivered strong growth, while new growth areas are beginning to ramp. As AI datacenters transition from copper to optical connectivity, Coherent’s broad photonics platform and manufacturing scale position us to help customers meet rising needs for bandwidth and energy efficiency. We expect fiscal 2027 pro forma revenue growth to exceed 60%.”
Jim Anderson, CEO
“Our Q1 results delivered substantial operating leverage and durable gross margin expansion, driven by pricing optimization and cost improvements. This margin strength gives us the confidence to raise our longer-term target. We expect to achieve our first quarter with non-GAAP gross margin above 45% before the end of calendar 2028.”
Runway Growth Finance Corp. declared a regular quarterly cash dividend of $0.33 per share for the fourth quarter of 2026. The dividend is payable on December 3, 2026, to stockholders of record as of November 17, 2026.
Cytokinetics reported Q3 2026 financial results, highlighted by $44.5 million in net product revenue from MYQORZO (aficamten). The company ended the quarter with approximately $1.6 billion in cash and plans to submit a supplemental NDA for aficamten in non-obstructive HCM in Q4 2026.
Term
Q3 2026
“Our third quarter results demonstrate continued strong execution as Cytokinetics enters its next phase of growth as a global specialty cardiology biopharmaceutical company.”
Robert I. Blum, Cytokinetics’ President and Chief Executive Officer
“In the U.S., the launch of MYQORZO continued to build solid momentum and increased velocity with growing adoption across a broadening base of prescribers.”
Robert I. Blum, Cytokinetics’ President and Chief Executive Officer
Fermi Inc. reported results from its 2026 Annual Meeting where shareholders ratified Ernst & Young LLP as auditors but failed to elect two Class I directors, Jeffrey S. Stein and Rick Perry, as they did not receive a majority of outstanding shares. The company alleges that certain investors, including TMNN Manager LLC and the MN Trust, breached a Director Nomination Agreement by voting against Governor Perry, and it reserves the right to seek legal remedies to give effect to the required votes.
LuxExperience B.V CEO Michael Kliger Sells $183K of Stock
Michael Kliger, CEO, sold 18,237 shares of LuxExperience B.V. at $10.00 to $10.01 a share (average $10.01) in 2 transactions, worth $183K in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 0 (-100.0%).
DoorDash Director Stanley Tang Sells $4.36M of Stock
Stanley Tang, Director, sold 23,125 shares of DoorDash, Inc. at $178.35 to $190.81 a share (average $188.71) in 11 transactions, worth $4.36M in total on Nov 2, 2026. Shares held after the trade: 10,361 (-1.9%).
Andy Fang, Director, sold 5,000 shares of DoorDash, Inc. at $181.17 a share, worth $906K in total on Nov 2, 2026. Shares held after the trade: 0 (-100.0%).
Clipper Realty Inc. reported record quarterly revenues of $40.5 million for Q3 2026, driven by strong residential leasing demand and high occupancy. The company reported a net loss of $5.9 million, partly impacted by the ongoing resolution of lender issues at its 250 Livingston Street office property following a major lease termination in 2025.
“For the quarter, the main highlights are continued strong residential leasing and significant progress made towards resolving lender issues at our 250 Livingston Street office property. The residential properties continued to have high occupancy and strong renter demand. New free market leases exceeded previous rents by 9% and renewals by over 5% and our major residential properties are leased at very high levels. Furthermore, our new Prospect House property at 953 Dean Street in Brooklyn, NY is fully operational after going in service last year.”
David Bistricer, Co-Chairman and Chief Executive Officer
PureCycle Technologies reported Q3 2026 revenue of $2.3 million, with production at its Ironton facility reaching 5.2 million pounds of resin. The company also announced the appointment of Fernando Musa as Executive Chairman to support commercial activities and strategic goals through 2027.
Qualcomm highlights significant risks related to its internal manufacturing facilities for RFFE modules and RF filters, noting that a higher portion of fixed costs compared to a fabless model could lead to lower gross profits during demand downturns. The company also emphasizes vulnerabilities to environmental regulations, climate change impacts, geopolitical conflicts, and increasingly sophisticated cybersecurity threats that could disrupt production or compromise intellectual property.
Sinclair reported record Q3 2026 results driven by $136 million in political advertising revenue, a 55% increase over the 2022 mid-term cycle. The company raised its full-year 2026 Adjusted EBITDA guidance to $825-$835 million and announced it has decided not to pursue a standalone spin-off of its Ventures portfolio at this time.
Term
Q3 2026
“Sinclair delivered strong third quarter results, with record mid-term political advertising revenue in both third and fourth quarters, and disciplined execution across the business. Political advertising revenue is expected to exceed our prior record year of 2024 as battleground races and the overall political environment helped drive record demand across our footprint. In addition, we have reached new network affiliation agreements with both ABC and CBS in recent weeks. Lastly, we are increasing our full year 2026 Adjusted EBITDA guidance to a range of $825 million to $835 million, which we note is higher than our 2024 Adjusted EBITDA of $816 million excluding the Diamond-related management fees received in that year.”
Arcutis Biotherapeutics reported a significant turnaround for the nine months ended September 30, 2026, achieving a net income of $12.5 million compared to a net loss of $33.5 million in the prior year period. This growth was driven by a 55% increase in net product revenue to $379.2 million, though operating expenses also rose to $362.4 million due to higher selling, general, and administrative costs.
FatPipe Inc. reported revenues of $9.87 million for the six months ended September 30, 2026, a 25% increase compared to the prior year. Net income for the same period rose significantly to $2.43 million, up from $0.70 million, despite a net decrease in cash driven by increased contracts receivable.
Generate Biomedicines Director Frances Arnold Sells $185K of Stock
Frances Arnold, Director, sold 11,409 shares of Generate Biomedicines, Inc. at $16.19 a share, worth $185K in total on Oct 29, 2026. Shares held after the trade: 220,063 (-4.9%).
Stoke Therapeutics CMO Barry Ticho Sells $185K of Stock
Barry Ticho, CMO, sold 6,995 shares of Stoke Therapeutics, Inc. at $26.38 a share, worth $185K in total on Nov 2, 2026. Shares held after the trade: 12,064 (-36.7%).
BioCryst Pharmaceuticals reported 257,299,269 shares of common stock outstanding as of October 30, 2026. The filing highlights the commercialization of ORLADEYO, the strategic merger with Astria, and a shift toward prioritizing external innovation and clinical development of product candidates like navenibart.
Hewlett Packard Enterprise's Board of Directors declared a cash dividend of $0.953125 per share on its 7.625% Series C Mandatory Convertible Preferred Stock. The dividend is payable on December 1, 2026, to shareholders of record as of November 15, 2026.
Regeneron Pharmaceuticals EVP General Counsel and Secret Joseph J. Larosa Sells $4.31M of Stock
Joseph J. Larosa, EVP General Counsel and Secret, sold 4,466 shares of Regeneron Pharmaceuticals, Inc. at $965.41 to $966.11 a share (average $965.49) in 2 transactions, worth $4.31M in total on Nov 2, 2026. Shares held after the trade: 38,906 (-1.3%).
Pattern Group Inc. reported record third-quarter 2026 revenue of $886 million, a 38% increase year-over-year, driven by strong net revenue retention of 127%. The company achieved net income of $32 million and raised its full-year 2026 revenue guidance to a range of $3.50 billion to $3.52 billion.
Term
Q3 2026
“We delivered another record quarter, with revenue of $886 million, up 38% year over year with net revenue retention of 127%. We’re helping existing brand partners grow while more brands choose Pattern to expand their businesses across marketplaces and geographies. This strong momentum underpins our increased full-year outlook.”
Dave Wright, Co-Founder and CEO
“Our record top line performance translated to strong bottom line delivery and meaningful free cash flow generation. On a trailing twelve month basis, the business generated $106 million of free cash flow, enabling us to invest for growth and return value to shareholders. We are raising our full year outlook, underscoring the power of Pattern’s model and our commitment to driving durable growth and long-term shareholder value.”